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Methylation-Mediated Silenced PYCARD Plays a Key Role in Human Prostate 
Cancer
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Indole derivative mitochonic acid MA-5 protects cell death of skin fibroblasts from 







































Hydrocortisone and Dexamethasone Dose-dependently Stabilize Mast Cells 
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The Chronic Heart Failure Analysis and Registry in the Tohoku District-2
-Multicenter, Prospective, Observational Study-






(2) (2) Stage-B: 器質的心疾患を有するが、心不全の症状を示さない症例
(3) (3) Stage-C: 器質的心疾患を有し、心不全の症状を有する症例
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